We have finally received the Foundation One results. They listed 3 genomic findings of CDKN2A/B loss, microsatellite status MS-Stable, Tumor Mutation Burden-intermediate; 8 muts. There were no FDA approved or potential clinical trials. We have about 30 pages of medical terminology that we dont understand. I wish they would provide some insight on what this means.
My dad passed Feb 23 from complications of this disease. He was on his 3 rd treatment of carbo/Jevtana. Following the treatment his WBC dropped to 0.08 and platelets to 11,000 then to 1,000, went into septic shock from acquiring an infection in his gut.
My dad was diagnosed at 65 yrs old in 2011. He chose radiation and hormone therapy at the time and always regretted not having it removed. I don’t know his Gleason score but it was either 7 or 9. He did well until It metastasized in 2015 with a PSA of 800 to his spine, rib cage, pelvis, and femur. According to mother, they tried casodex, Lupron, Zytega, Radium 223, Taxotere, Cabizitaxel, Xtandi, and a cabazitaxel/carbo cocktail when it has spread to adrenal glands.
My dad became blood transfusion dependent from 2016-Feb 2018, requiring 1-2 units (bags) every Monday. This made my dad incredibly tired all of the time and decreased his overall functional mobility.
I’m not in the medical field, but how does one become blood transfusion dependent prior to chemo?
Also, my dads biggest regret was not having removal. Would that have helped him?
Thank you and thanks for your understanding as I’m trying to still comprehend it all and navigate around in this life without my Dad.